Cantourage Group SE has started its cooperation with Jacoby
GM in Austria and carried out the first export of dronabinol and the
dronabinol solution here. Dronabinol is pure tetra-hydro-cannabidiol, better known as THC. As a result, the solution has now been shipped to the second country in a year and the third country since its launch. Cantourage first entered the Croatian cannabis pharmaceutical market in April 2023. With this expansion, Cantourage is strengthening its own position in the European market for medicinal cannabis and successfully implementing its internationalization strategy.
Cantourage supplies to Jacoby GM Pharma GmbH, a leading
Austrian pharmaceutical wholesaler. With around 490 employees, sales of approximately EUR 400 million in 2021, and a total of 7 locations in Austria, Jacoby GM is a strong and established player on the Austrian pharmaceutical market. Jacoby’s business fields include pharmacies, home pharmacies, veterinary medicine, aesthetic medicine, industry, and import services.
The introduction of the dronabinol solution is intended to offer new
alternatives for dronabinol prescriptions. Jacoby GM’s nationwide distribution ensures that Austrian pharmacies and pharmaceutical wholesalers can be supplied with the product.
“We are very happy that we were able to gain such an experienced and extremely well-established partner as Jacoby GM for the nationwide market entry with dronabinol and the dronabinol solution in Austria,” said Sebastian Blöte, European Sales Director of Cantourage added: “Our goal is to overturn the currently still existing dronabinol monopolies in many European countries and be able to offer pharmacies this innovative form of dronabinol by significantly simplifying the production process. We are therefore very happy to be working with Jacoby GM, who shares our ambitious vision.”
For more information: